Medical Imaging Convention [rescheduled] Sep 15, 2021 - Sep 16, 2021 — National Exhibition Centre, Birmingham, England
2021 SINAPSE ASM Sep 16, 2021 - Sep 17, 2021 — Technology & Innovation Centre, University of Strathclyde, 99 George Street, Glasgow
Total Body PET 2021 conference [rescheduled] Sep 22, 2021 - Sep 24, 2021 — Virtual Meeting (online)
PET is Wonderful Annual Meeting 2021 Oct 26, 2021 12:00 AM — Virtual Meeting (online)


SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.

Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index A Randomized Controlled Trial

Author(s): F. G. R. Fowkes, J. F. Price, M. C. W. Stewart, I. Butcher, G. C. Leng, A. C. H. Pell, P. A. G. Sandercock, K. A. A. Fox, G. D. O. Lowe, G. D. Murray, Aspirin Asymptomatic Atheroscleros

Context A low ankle brachial index (ABI) indicates atherosclerosis and an increased risk of cardiovascular and cerebrovascular events. Screening for a low ABI can identify an asymptomatic higher risk group potentially amenable to preventive treatments. Objective To determine the effectiveness of aspirin in preventing events in people with a low ABI identified on screening the general population. Design, Setting, and Participants The Aspirin for Asymptomatic Atherosclerosis trial was an intention-to-treat double-blind randomized controlled trial conducted from April 1998 to October 2008, involving 28 980 men and women aged 50 to 75 years living in central Scotland, free of clinical cardiovascular disease, recruited from a community health registry, and had an ABI screening test. Of those, 3350 with a low ABI (<= 0.95) were entered into the trial, which was powered to detect a 25% proportional risk reduction in events. Interventions Once daily 100 mg aspirin ( enteric coated) or placebo. Main Outcome Measures The primary end point was a composite of initial fatal or nonfatal coronary event or stroke or revascularization. Two secondary end points were ( 1) all initial vascular events defined as a composite of a primary end point event or angina, intermittent claudication, or transient ischemic attack; and ( 2) all-cause mortality. Results After a mean (SD) follow-up of 8.2 (1.6) years, 357 participants had a primary end point event (13.5 per 1000 person-years, 95% confidence interval [CI], 12.2-15.0). No statistically significant difference was found between groups (13.7 events per 1000 person-years in the aspirin group vs 13.3 in the placebo group; hazard ratio [HR], 1.03; 95% CI, 0.84-1.27). Avascular event comprising the secondary end point occurred in 578 participants (22.8 per 1000 person-years; 95% CI, 21.0-24.8) and no statistically significant difference between groups ( 22.8 events per 1000 person-years in the aspirin group vs 22.9 in the placebo group; HR, 1.00; 95% CI, 0.85-1.17). There was no significant difference in all-cause mortality between groups ( 176 vs 186 deaths, respectively; HR, 0.95; 95% CI, 0.77-1.16). An initial event of major hemorrhage requiring admission to hospital occurred in 34 participants (2.5 per 1000 person-years) in the aspirin group and 20 (1.5 per 1000 person-years) in the placebo group ( HR, 1.71; 95% CI, 0.99-2.97). Conclusion Among participants without clinical cardiovascular disease, identified with a low ABI based on screening a general population, the administration of aspirin compared with placebo did not result in a significant reduction in vascular events. Trial Registration Identifier: ISRCTN66587262 JAMA. 2010;303(9):841-848

Full version: Available here

Click the link to go to an external website with the full version of the paper

ISBN: 0098-7484
Publication Year: 2010
Periodical: Jama-Journal of the American Medical Association
Periodical Number: 9
Volume: 303
Pages: 841-848
Author Address: Fowkes, FGR Univ Edinburgh, Ctr Populat Hlth Sci, Wolfson Unit Prevent Peripheral Vasc Dis, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland Univ Edinburgh, Ctr Populat Hlth Sci, Wolfson Unit Prevent Peripheral Vasc Dis, Edinburgh EH8 9AG, Midlothian, Scotland Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh EH8 9AG, Midlothian, Scotland Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH8 9AG, Midlothian, Scotland London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England Monklands Hosp, Dept Cardiol, Airdrie, Lanark, Scotland Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland